title: Toxic pediatric parkinsonism: report of a child with metabolic studies and response to treatment.
abstract: We successfully treated a child with parkinsonism secondary to cytosine arabinoside with levodopa/carbidopa and attempted to elucidate the pathogenesis of the disorder by sequential analysis of cerebrospinal fluid biogenic amines, sequential magnetic resonance imaging, and fluorodopa positron emission tomography, which revealed both permanent and reversible biochemical and structural alterations. The parkinsonian disorder resolved in 9 months. Metabolic changes and structural abnormalities on imaging studies were chronologically correlated with the clinical course.
authors.affiliation: Division of Pediatric Neurology, Weill Medical College of Cornell University, New York, New York, USA.
authors.forename: Abe M
authors.initials: AM
authors.lastname: Chutorian
authors.forename: Aviva
authors.initials: A
authors.lastname: Bojko
authors.forename: Linda
authors.initials: L
authors.lastname: Heier
authors.forename: Steven
authors.initials: S
authors.lastname: Frucht
authors.forename: Toby
authors.initials: T
authors.lastname: Nygaard
authors.forename: David
authors.initials: D
authors.lastname: Edelberg
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000978:Antiparkinson Agents / Q000008:administration & dosage; D002230:Carbidopa / Q000008:administration & dosage; D002648:Child; D003561:Cytarabine / Q000009:adverse effects*; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000978:Antiparkinson Agents; D003561:Cytarabine; D007980:Levodopa; D002230:Carbidopa